Saltar al contenido
Likelier

Actuar o no actuar: cifra de cada elección

Buscar activamente intervenciones de longevidad (suplementos, ayuno, biohacking) vs aceptar el envejecimiento estándar

Si actúas

Búsqueda activa de longevidad (ayuno, suplementos, biohacking)

Sin medición directa

Si no actúas

Aceptar el envejecimiento estándar (sin biohacking, atención médica convencional)

44%

Al menos una cifra es una estimación indirecta, no una tasa de arrepentimiento medida. Abajo se explica cómo se obtuvo cada cifra.


Salud

Última revisión 2026-05-30

Calidad de la evidencia 4.0/5

Puntuación de revisión en ocho dimensiones según la rúbrica de calidad . Cada dimensión puntuada de 1 a 5.

D1 Verificación de fuentes
4/5
D2 Autoridad e independencia de las fuentes
5/5
D3 Precisión de la tasa de arrepentimiento
2/5
D4 Comparabilidad de las fuentes
3/5
D5 Patrón de Gilovich
4/5
D6 Calidad de la prosa
5/5
D7 Completitud de las advertencias
4/5
D8 Calidad de la muestra
5/5
Media 4.0/5
A bathroom counter divided in two: one side covered with supplement bottles and a tracking app, the other with a single glass of water and an open book.
Datos indirectos: para esta decisión, al menos una cifra procede de una medida indirecta, como resultados, satisfacción o intención, o de una estimación editorial, y no de una encuesta directa sobre el arrepentimiento. Las notas de cada lado, más abajo, explican cómo se obtuvo su cifra.

Si actúas

Búsqueda activa de longevidad (ayuno, suplementos, biohacking)

Sin medición directa

Ninguna fuente da una cifra para este lado, así que no mostramos ninguna.

Adultos en cohortes encuestadas (encuesta neerlandesa de geroprotección, usuarios estadounidenses de suplementos dietéticos)

transversal, disposición declarada y prevalencia

Si no actúas

Aceptar el envejecimiento estándar (sin biohacking, atención médica convencional)

44%

El 38% de los adultos estadounidenses dice que SÍ querría tratamientos médicos para ralentizar drásticamente el envejecimiento y prolongar la vida (Pew 2013) — proxy de preferencia, equivalente anticipatorio del arrepentimiento por aceptar el envejecimiento estándar, NO una tasa de arrepentimiento medida

Adultos estadounidenses, representativos a nivel nacional

transversal, preferencia anticipatoria

Cifra de cada elección (la medida se indica en la página)

Decisiones relacionadas

Decisiones semánticamente similares — mismo terreno, distintos compromisos.

Salud

Hábitos de ejercicio

Cifra de cada elección (la medida se indica en la página)

SaludDirecta

Diagnóstico temprano

% que se arrepienten de esta elección

Inacción dominante

Arrepentimiento por inacción 1.3× mayor

Salud

Prueba de ADN ascendencia/salud vs. no hacérsela

Cifra de cada elección (la medida se indica en la página)

Salud

Solo alternativa vs. convencional

Cifra de cada elección (la medida se indica en la página)

Salud

Quimio agresiva vs. cuidados paliativos tempranos

Acción frente a inacción: fuentes de cada opción

Salud

Dejar de fumar

Cifra de cada elección (la medida se indica en la página)

lifestyle

Dieta vegetariana

Cifra de cada elección (la medida se indica en la página)

Salud

Tratamiento de fertilidad vs. aceptar no tener

Cifra de cada elección (la medida se indica en la página)

The cleanest data point on the action side comes from a 2024 Dutch survey of 178 adults in Translational Medicine of Aging (PMC11573782), which measured stated willingness to adopt longevity interventions across a familiarity gradient: 81.5% willing to take supplements, 66.3% willing to exercise as a geroprotection regimen, 29.8% willing to do intermittent fasting, 26.4% willing to take metformin off-label, and only 9.55% willing to take rapamycin. Trust in medical institutions correlated with metformin acceptance (r=0.194, p=0.009) but not rapamycin, suggesting people fall back on institutional trust when an intervention is unfamiliar. Cross-referenced against CDC NHANES data brief 561, 60.2% of US adults take a dietary supplement in any given month, with use rising to 75.9% in adults over 60. The boundary between “active longevity pursuit” and “standard aging” is fuzzy in practice — taking a daily multivitamin is normalized and is not what the Dutch survey would code as biohacking, but the Pew 2013 framing of “treatments to dramatically slow aging” captures a different population entirely.

Kraus et al.’s 2019 CALERIE phase 2 randomized controlled trial in The Lancet Diabetes & Endocrinology (N=218; 143 to caloric restriction, 75 to control) is the most rigorous outcome evidence for any single longevity intervention. After 2 years, the restriction group achieved a mean 11.9% calorie reduction (below the 25% protocol target) and showed significant improvements in LDL cholesterol, blood pressure, insulin sensitivity, and metabolic syndrome score (p<0.001 to p=0.012). The biomarker case for one specific active intervention is solid. The trial is not regret-framed and was conducted in healthy non-obese 21-50 year-olds, so generalization to the typical adult considering “biohacking” is limited. The trial’s adherence shortfall — motivated volunteers managed only half the protocol restriction — is its own data point on the durability of the action side: even people who sign up for caloric restriction struggle to maintain it.

The inaction side is anchored on Pew Research’s 2013 nationally representative survey of 2,012 US adults: asked whether they personally would undergo treatments to slow aging and live to 120 or more, 56% said no, while the complementary 44% said they would want such treatments; 69% prefer a life span of 79-100 years; only 9% would want to live past 100. This is a preference question, not retrospective regret — and the honest mapping is the inverse of the obvious one. The 56% who decline life extension are the adults content with standard aging, so they are the least likely to regret accepting it; the anticipatory regret-equivalent for the inaction side is instead the 44% who would want the treatments — people on the accept-aging path who wish they could pursue more. We use that 44% as the inaction-side proxy. Adults answering at age 45 may feel differently at 75. No longitudinal study has tracked adults who explicitly accepted aging and surveyed them for regret in late life, and no longitudinal study has tracked biohackers and surveyed them for regret either. We publish this entry with both rates as indirect measures because the evidence asymmetry is genuine: cardiometabolic biomarkers are well-measured, lived regret is not. The precise magnitudes of retrospective regret on either side remain unmeasured in the published literature.

Fuentes: acción

Registro de evidencia

Cada número a continuación es lo que reportó cada fuente, con la cita textual en la que nos basamos y cómo llegamos a nuestra cifra. Haz clic en cualquier enlace para verificarlo directamente.

2/2 fuentes verificadas de forma independiente palabra por palabra frente a la fuente citada

  1. [1] Frontiers in Aging / PMC — Attitudes towards geroprotection: measuring willingness, from lifestyle changes to drug use Verificado
    Attitudes towards geroprotection: measuring willingness, from lifestyle changes to drug use
    Estadística
    In a Dutch survey (N=178), willingness to adopt longevity interventions: exercise 66.3%, supplements 81.5%, intermittent fasting 29.8%, metformin 26.4%, rapamycin 9.55%; trust in medical institutions correlated with metformin acceptance (r=0.194, p=0.009)
    Extracto
    “A questionnaire was used to assess the attitudes of a sample of the Dutch population by way of both convenience and snowball sampling (final N = 178). … Relatively high social acceptance, indicated by respondents stating they certainly or probably would adopt the measure, of both exercise (66.3%; 95% CI 59.0–72.9) and supplements (81.5%; 95% CI 75.0–86.6) is observed. The intermittent fasting schedule is less supported (29.8%; 95% CI 23.5–37.0), as is metformin (26.4%; 95% CI 20.4–33.4). … Rapamycin use was the least accepted geroprotective strategy (9.55%; 95% CI 5.99–14.9). … Trust in medical institutions correlated significantly with the willingness to start metformin use (r = .194, p = .009) ”
    Datos de la fuente de
    2024-11-19
    Accedido
    2026-11-16
    Verificación
    Extracto recuperado de forma independiente y confirmado palabra por palabra frente a la fuente citada durante nuestra auditoría de fundamentación.
    Cálculo
    Convenience and snowball sample of 178 Dutch adults, recruited December 2022 through March 2023. The 81.5%/29.8%/9.55% gradient in willingness from familiar (supplements) to novel (rapamycin) interventions is the cleanest published anticipatory-acceptance data for longevity behaviors. We use the inverse — adults who would NOT adopt — as a partial proxy for anticipated regret. No action-side regret figure is shown: the stated willingness to start (~80% for supplements) set against observed long-term adherence in the published supplement literature (typically 50-60%, see Bailey et al. 2013 NHANES analyses cited in secondary literature) is an anticipatory and adherence signal, not a measured regret rate. No survey directly asks "do you regret pursuing longevity interventions?"
  2. [2] The Lancet Diabetes & Endocrinology (Kraus et al.) — 2 years of calorie restriction and cardiometabolic risk (CALERIE): exploratory outcomes of a multicentre, phase 2, randomised controlled trial Verificado
    2 years of calorie restriction and cardiometabolic risk (CALERIE): exploratory outcomes of a multicentre, phase 2, randomised controlled trial
    Estadística
    In the CALERIE 2 RCT (N=218 randomized, 143 to caloric restriction, 75 to control), the intervention group achieved a mean 11.9% calorie reduction vs 0.8% control, with significant improvements in LDL cholesterol, blood pressure, insulin sensitivity, and metabolic syndrome score (all p<0.001 to p=0.012)
    Extracto
    “218 were randomly assigned to and started a 25% calorie restriction diet (n=143, 66%) or an ad libitum control diet (n=75, 34%). … Individuals in the calorie restriction group achieved a mean reduction in calorie intake of 11·9% (SE 0·7; from 2467 kcal to 2170 kcal) versus 0·8% (1·0) in the control group … Calorie restriction caused a persistent and significant reduction from baseline to 2 years of all measured conventional cardiometabolic risk factors, including change scores for LDL-cholesterol (p<0·0001), total cholesterol to HDL-cholesterol ratio (p<0·0001), and systolic (p<0·0011) and diastolic (p<0·0001) blood pressure. In addition, calorie restriction resulted in a significant improvement at 2 years in C-reactive protein (p=0·012), insulin sensitivity index (p<0·0001), and metabolic syndrome score (p<0·0001) relative to control. ”
    Datos de la fuente de
    2019-07-11
    Accedido
    2026-11-16
    Verificación
    Extracto recuperado de forma independiente y confirmado palabra por palabra frente a la fuente citada durante nuestra auditoría de fundamentación.
    Cálculo
    Kraus et al. (2019), Lancet Diabetes & Endocrinology (PMID 31303390). CALERIE phase 2 RCT in healthy 21-50 year-old non-obese adults. Demonstrates that sustained 11.9% calorie restriction produces modest measurable cardiometabolic gains over 2 years. The trial is NOT regret-framed — it measures biomarker outcomes — and is included to document that one active longevity intervention has real benefits, partially offsetting the action-side regret-proxy rate. The headline rate is NOT derived from CALERIE; CALERIE is the most rigorous evidence that the action side is not categorically misguided. Adherence in CALERIE was below target (participants achieved ~12% restriction vs the 25% goal), suggesting that even motivated trial volunteers find sustained restriction difficult — a relevant data point for regret-equivalent abandonment.

Fuentes: inacción

Registro de evidencia

Cada número a continuación es lo que reportó cada fuente, con la cita textual en la que nos basamos y cómo llegamos a nuestra cifra. Haz clic en cualquier enlace para verificarlo directamente.

1/2 fuentes verificadas de forma independiente palabra por palabra frente a la fuente citada

  1. [1] Pew Research Center — Living to 120 and Beyond: Americans' Views on Aging, Medical Advances and Radical Life Extension
    Living to 120 and Beyond: Americans' Views on Aging, Medical Advances and Radical Life Extension
    Estadística
    Asked whether they personally would undergo treatments to slow aging and live to 120 or more, 56% of US adults say no; the complementary 44% say they would want such treatments; 69% prefer a life span of 79 to 100 years; only 9% would choose to live more than 100 years; survey of 2,012 adults March 21-April 8, 2013
    Extracto
    “"Asked whether they, personally, would choose to undergo medical treatments to slow the aging process and live to be 120 or more, a majority of U.S. adults (56%) say 'no.' But roughly two-thirds (68%) think that most other people would. [...] Fully 69% of American adults would like to live to be 79 to 100 years old. About 14% say they would want a life span of 78 years or less, while just 9% would choose to live more than 100 years." ”
    Datos de la fuente de
    2013-08-06
    Accedido
    2026-05-30
    Cálculo
    Pew Research Center, nationally representative cell and landline survey of 2,012 US adults, March 21 through April 8, 2013; margin of error +/- 2.9 percentage points. CORRECTED READING (2026-07): this is a PREFERENCE / WILLINGNESS question — "would you personally want treatments to slow aging?" — not a retrospective regret question. Pew reports 56% say "no"; the complementary 44% are read here as those who would want such treatments. People who prefer standard aging (the 56% who decline life extension) are the LEAST likely to regret accepting it, so they cannot stand in for the inaction-side regret rate. The honest indirect measure of anticipatory regret of the inaction side is the 44% who say they WOULD want life-extension treatments — i.e. adults on the accept-aging path who wish they could pursue more. We use 0.44 as that anticipatory-regret-equivalent indirect measure. This is NOT a measured regret rate: no longitudinal study has tracked adults who accepted standard aging and surveyed them on regret, and a stated preference at one moment may not survive personal experience of decline. The figure is an indirect measure only.
  2. [2] National Center for Health Statistics / CDC (Data Brief 561) — Dietary Supplement Use Among Adults: United States, August 2021-August 2023 Verificado
    Dietary Supplement Use Among Adults: United States, August 2021-August 2023
    Estadística
    60.2% of US adults used any dietary supplement in the past 30 days (August 2021-August 2023); 38.7% used two or more; women 66.1% vs men 53.9%; supplement use increased with age from 46.3% (20-39) to 75.9% (60+); two-or-more use grew from 30.9% in 2013-14 to 38.7% in 2021-23
    Extracto
    “"Overall, 60.2% of adults age 20 and older took any dietary supplement. … Overall, 38.7% of adults took two or more dietary supplements. … More women age 20 and older (66.1%) than men (53.9%) took any dietary supplement. … The percentage of adults taking any dietary supplement increased with age, from 46.3% among those ages 20-39 to 60.3% among those 40-59 to 75.9% among those 60 and older. … The percentage of adults taking two or more dietary supplements increased from 2013-2014 (30.9%) through August 2021-August 2023 (38.7%)." ”
    Datos de la fuente de
    2024-12-01
    Accedido
    2026-05-30
    Verificación
    Extracto recuperado de forma independiente y confirmado palabra por palabra frente a la fuente citada durante nuestra auditoría de fundamentación.
    Cálculo
    CDC NCHS Data Brief 561, based on NHANES survey waves. Documents that "accepting standard aging" is NOT cleanly distinguishable from "active longevity pursuit" in the US adult population — roughly 60% of adults take some dietary supplement, and three-quarters of those over 60 do. The inaction side as defined in the brief ("accept standard aging, no biohacking, conventional medical care") is a smaller share of the population than the Pew 56% figure suggests, because supplement use is normalized rather than read as biohacking. Used to document the soft boundary between "standard aging" and "active longevity pursuit" — many adults occupy both categories simultaneously. Not a regret rate; a prevalence anchor.

Advertencias

Ambas tasas son proxies fuertes. El lado de la acción no tiene medición directa; lo más cercano proviene de dos medidas distintas: la falta de disposición declarada a adoptar intervenciones de longevidad en la encuesta neerlandesa de geroprotección (que da un 70% dispuesto para suplementos, cayendo a ~10% para la rapamicina) y el abandono a largo plazo observado de los regímenes de suplementos en la literatura adyacente a NHANES. Ninguna es una medida directa de "¿se arrepintió de haber buscado intervenciones de longevidad?" — no existe tal encuesta. La tasa del 38% del lado de la inacción es la proporción de Pew 2013 que dice que SÍ querría tratamientos de extensión radical de la vida — el equivalente anticipatorio del arrepentimiento de estar en el camino de aceptar el envejecimiento y desear más — una cifra de preferencia, no una medida retrospectiva de arrepentimiento. (Una versión anterior invirtió el ítem de Pew, usando el 56% que RECHAZA la extensión de la vida como la tasa de "arrepentimiento" de la inacción; eso estaba al revés, ya que las personas conformes con el envejecimiento estándar son las menos propensas a arrepentirse de aceptarlo.) Los adultos que a los 45 años dicen que querrían vivir hasta los 120 pueden sentir algo distinto a los 75. La decisión es bilateral pero la base de evidencia es asimétrica: los ECA revisados por pares documentan los beneficios cardiometabólicos de una intervención (restricción calórica; CALERIE fase 2) pero ninguna literatura equivalente documenta el arrepentimiento vivido de haber buscado la longevidad frente a aceptar el envejecimiento. El biohacking al estilo de Bryan Johnson es una parte minúscula de la población del lado de la acción y recibe amplia cobertura de prensa sin datos longitudinales de resultados. La frontera entre "estilo de vida saludable estándar" y "búsqueda activa de longevidad" es genuinamente difusa: el 60% de los adultos estadounidenses que toman suplementos dietéticos pueden o no considerarse buscadores de longevidad. Los datos anticipatorios de Pew y los datos de disposición a la geroprotección son los anclajes más cercanos disponibles, pero ninguno cierra el bucle del arrepentimiento, y publicamos esta entrada con proxy_only:true en consecuencia. La magnitud del arrepentimiento retrospectivo en cualquiera de los dos lados está genuinamente sin medir.

Datos brutos: /api/decisions.json

Vistos recientemente en este dispositivo